Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.

BACKGROUND Plasma levels of D-dimer, the primary degradation product of cross-linked fibrin, are elevated in several acute thrombotic disorders. However, whether elevated D-dimer levels among healthy individuals are associated with future coronary thrombosis is unknown. METHODS AND RESULTS To evaluate whether levels of D-dimer are associated with the occurrence of future myocardial infarction (MI) among apparently healthy men, levels were measured in plasma samples collected at baseline from 296 participants in the Physicians' Health Study who later developed a first MI and from an equal number of age- and smoking status-matched control subjects who remained free of vascular disease during a mean follow-up period of 60.2 months. In univariate analyses, baseline plasma concentrations of D-dimer in the upper ranges of normal were associated with elevated risks of MI. Specifically, the relative risk of future MI for individuals with baseline D-dimer concentration exceeding the 95th percentile of the control distribution was two times higher than that of individuals with lower levels (relative risk [RR], 2.02; 95% confidence interval [CI], 1.04 to 4.02; P = .04). This association persisted in multivariate analyses controlling for nonlipid cardiovascular risk factors (RR, 2.12; 95% CI, 1.05 to 4.28; P = .04) and for lipoprotein(a) (RR, 2.02; 95% CI, 1.04 to 3.94; P = .03). In contrast, this association was attenuated and no longer statistically significant in analyses that controlled for total and high-density lipoprotein cholesterol (RR, 1.74; 95% CI, 0.78 to 3.91; P = .2) or for endogenous tissue-type plasminogen activator and its primary inhibitor, plasminogen activator inhibitor type 1 (RR, 1.58; 95% CI, 0.67 to 3.77; P = .3). CONCLUSIONS Elevated levels of D-dimer are associated with increased risks of future MI, although they do not appear to be an independent predictor when other risk factors are considered. As the presence of D-dimer in plasma reflects ongoing fibrin degradation, these data support the hypothesis that activation of the endogenous fibrinolytic system occurs many years in advance of coronary arterial occlusion.

[1]  P. Ridker,et al.  A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.

[2]  P. Elwood,et al.  Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. , 1991, Circulation.

[3]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[4]  E. B. Smith,et al.  Fate of fibrinogen in human arterial intima. , 1990, Arteriosclerosis.

[5]  D. Slosman,et al.  Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism , 1991, The Lancet.

[6]  W. Willett,et al.  A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. , 1991, The New England journal of medicine.

[7]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[8]  C. Francis,et al.  A Molecular Model of Plasmic Degradation of Crosslinked Fibrin , 1982, Seminars in thrombosis and hemostasis.

[9]  J. Manson,et al.  Baseline Fibrinolytic State and the Risk of Future Venous Thrombosis: A Prospective Study of Endogenous Tissue‐Type Plasminogen Activator and Plasminogen Activator Inhibitor , 1992, Circulation.

[10]  A. Rumley,et al.  Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease , 1993, The Lancet.

[11]  D. Rylatt,et al.  Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems , 1985, British journal of haematology.

[12]  J. Erikssen,et al.  Blood Platelet Count and Function Are Related to Total and Cardiovascular Death in Apparently Healthy Men , 1991, Circulation.

[13]  J. T. ten Cate,et al.  A Comparative Analysis of D-Dimer Assays in Patients with Clinically Suspected Pulmonary Embolism , 1993, Thrombosis and Haemostasis.

[14]  R. Bick The Clinical Significance of Fibrinogen Degradation Products , 1982, Seminars in thrombosis and hemostasis.

[15]  P. Ridker,et al.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction , 1993, The Lancet.

[16]  P. Mombaerts,et al.  Fibrinolytic Response and Fibrin Fragment D-Dimer Levels in Patients with Deep Vein Thrombosis , 1987, Thrombosis and Haemostasis.

[17]  J. Cooper,et al.  Antithrombin III and arterial disease , 1992, The Lancet.

[18]  J. Schapiro,et al.  Platelet hyperreactivity and prognosis in survivors of myocardial infarction. , 1990, The New England journal of medicine.

[19]  J. Loscalzo,et al.  Utility of cross-linked fibrin degradation products in the diagnosis of pulmonary embolism. , 1988, American heart journal.

[20]  P. de Moerloose,et al.  Measurement of plasma D-dimer for diagnosis of deep venous thrombosis. , 1989, American Journal of Clinical Pathology.

[21]  P. Ridker An epidemiologic assessment of thrombotic risk factors for cardiovascular disease , 1992 .

[22]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[23]  J. Manson,et al.  Prospective study of endogenous tissue plasminogen activator and risk of stroke , 1994, The Lancet.

[24]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[25]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[26]  P. Ridker,et al.  Hemostatic risk factors for coronary heart disease. , 1991, Circulation.